Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations

Aims/Introduction:  Eicosapentaenoic acid (EPA) stimulates glucagon‐like peptide‐1 (GLP‐1) secretion in mice. We investigated the relationship between serum EPA concentrations and the efficacy of dipeptidyl‐peptidase IV (DPP‐4) inhibitor in patients with type 2 diabetes.

• Publication year

  2012

• Venue

  Journal of Diabetes Investigation

• Publication date

  2012-05-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.2040-1124.2012.00220.xPMID 24843614PMCID 4015428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

  2012cited by this paper
• GIP and GLP‐1, the two incretin hormones: Similarities and differences

  2010cited by this paper
• Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area.

  2010cited by this paper
• Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

  2010cited by this paper
• Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

  2009cited by this paper
• Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction.

  2008cited by this paper
• Validation of self-reported energy intake by a self-administered diet history questionnaire using the doubly labeled water method in 140 Japanese adults

  2008cited by this paper
• Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes.

  2008cited by this paper
• Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study.

  2008cited by this paper
• Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion.

  2008cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• The Glucagon‐Like Peptides

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

  2006cited by this paper
• Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

  2005cited by this paper
• GLP-1 and Extra-islet Effects

  2004cited by this paper
• OMEGA‐3 FATTY ACIDS: THEIR ROLE IN THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS RELATED RISK FACTORS AND COMPLICATIONS

  2003cited by this paper
• n−3 Fatty acids and the prevention of coronary atherosclerosis

  2000cited by this paper
• n-3 fatty acids and the prevention of coronary atherosclerosis.

  2000cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

  1999cited by this paper
• Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

  1999cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Dietary Factors Determining Diabetes and Impaired Glucose Tolerance: A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study

  1995cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Inverse Association Between Fish Intake and Risk of Glucose Intolerance in Normoglycemic Elderly Men and Women

  1991cited by this paper
• Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues

  1990cited by this paper

• Deciphering the gene regulatory network associated with anti-apoptosis in the pancreatic islets of type 2 diabetes mice using computational approaches

  2023cites this paper
• James Lind Alliance research priorities: should diet and exercise be used as an alternative to drugs for the management of type 2 diabetes or alongside them?

  2019cites this paper
• Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study

  2019cites this paper
• Eicosapentaenoic acid/arachidonic acid ratio and weight loss during hospitalization for glycemic control among overweight Japanese patients with type 2 diabetes: a retrospective observational study

  2019cites this paper
• Effects of metformin and alogliptin on body composition in people with type 2 diabetes

  2018cites this paper
• Relationship between deterioration of glycated hemoglobin‐lowering effects in dipeptidyl peptidase‐4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes

  2017cites this paper
• Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

  2017cites this paper
• Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives

  2016cites this paper
• Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: a multicenter, randomized trial

  2016cites this paper
• β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians

  2015cites this paper
• Why Are Incretin-Based Therapies More Efficient in East Asians? Perspectives from the Pathophysiology of Type 2 Diabetes and East Asian Dietary Habits

  2015cites this paper
• Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study

  2015cites this paper
• Alogliptin benzoate for the treatment of type 2 diabetes

  2014cites this paper
• Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study

  2014cites this paper
• Predictive clinical parameters for the hemoglobin A1c-lowering effect of vildagliptin in Japanese patients with type 2 diabetes

  2014cites this paper
• Alogliptin for the treatment of Type 2 diabetes

  2014cites this paper
• Incretin physiology and pathophysiology from an Asian perspective

  2014cites this paper
• Review: Evidence-based Clinical Research of Anti-obesity Supplements in Japan

  2013cites this paper
• Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes

  2013cites this paper
• Eicosapentaenoic acid improves glycemic control in elderly bedridden patients with type 2 diabetes.

  2013cites this paper